vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Syndax Pharmaceuticals Inc is the larger business by last-quarter revenue ($68.5M vs $34.3M, roughly 2.0× Clearfield, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -99.3%, a 97.5% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs -3.2%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
CLFD vs SNDX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $68.5M |
| Net Profit | $-614.0K | $-68.0M |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | -91.3% |
| Net Margin | -1.8% | -99.3% |
| Revenue YoY | -3.2% | 791.7% |
| Net Profit YoY | 67.8% | 27.8% |
| EPS (diluted) | $-0.04 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $68.5M | ||
| Q3 25 | $23.4M | $45.9M | ||
| Q2 25 | $49.9M | $38.0M | ||
| Q1 25 | $47.2M | $20.0M | ||
| Q4 24 | $29.7M | — | ||
| Q3 24 | $5.6M | $12.5M | ||
| Q2 24 | $48.8M | — | ||
| Q1 24 | $36.9M | $0 |
| Q4 25 | $-614.0K | $-68.0M | ||
| Q3 25 | $-9.1M | $-60.7M | ||
| Q2 25 | $1.6M | $-71.8M | ||
| Q1 25 | $1.3M | $-84.8M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-84.1M | ||
| Q2 24 | $-447.0K | — | ||
| Q1 24 | $-5.9M | $-72.4M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | -91.3% | ||
| Q3 25 | 10.3% | -125.2% | ||
| Q2 25 | 3.0% | -182.7% | ||
| Q1 25 | 0.6% | -417.9% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | — | -716.6% | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | -26.4% | — |
| Q4 25 | -1.8% | -99.3% | ||
| Q3 25 | -38.8% | -132.4% | ||
| Q2 25 | 3.2% | -189.3% | ||
| Q1 25 | 2.8% | -423.3% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -673.0% | ||
| Q2 24 | -0.9% | — | ||
| Q1 24 | -16.0% | — |
| Q4 25 | $-0.04 | $-0.78 | ||
| Q3 25 | $-0.65 | $-0.70 | ||
| Q2 25 | $0.11 | $-0.83 | ||
| Q1 25 | $0.09 | $-0.98 | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $-0.98 | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.40 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $64.6M |
| Total Assets | $268.1M | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $394.1M | ||
| Q3 25 | $106.0M | $436.0M | ||
| Q2 25 | $117.2M | $455.2M | ||
| Q1 25 | $112.0M | $512.2M | ||
| Q4 24 | $113.0M | — | ||
| Q3 24 | $129.0M | $389.6M | ||
| Q2 24 | $123.8M | — | ||
| Q1 24 | $142.9M | $434.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | $64.6M | ||
| Q3 25 | $256.2M | $115.4M | ||
| Q2 25 | $264.5M | $157.4M | ||
| Q1 25 | $265.9M | $215.1M | ||
| Q4 24 | $267.4M | — | ||
| Q3 24 | $275.8M | $366.4M | ||
| Q2 24 | $274.6M | — | ||
| Q1 24 | $279.2M | $491.9M |
| Q4 25 | $268.1M | $529.7M | ||
| Q3 25 | $306.2M | $551.8M | ||
| Q2 25 | $314.7M | $596.1M | ||
| Q1 25 | $310.9M | $640.7M | ||
| Q4 24 | $303.2M | — | ||
| Q3 24 | $315.3M | $425.8M | ||
| Q2 24 | $318.1M | — | ||
| Q1 24 | $315.4M | $543.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-69.5M |
| Free Cash FlowOCF − Capex | $-2.4M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $-69.5M | ||
| Q3 25 | — | $-70.5M | ||
| Q2 25 | $7.9M | $-87.8M | ||
| Q1 25 | $3.0M | $-95.2M | ||
| Q4 24 | $7.2M | — | ||
| Q3 24 | $22.2M | $-62.3M | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $-5.7M | $-83.5M |
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $654.0K | — | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $18.2M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-7.7M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 323.0% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -20.8% | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 71.4% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
